Abstract 10P
Background
Multi-gene expression tests have been widely accepted as risk-prediction tools in early-stage HR-positive and HER2-negative (HR+/HER2-) breast cancer (EBC) after surgery. This study compared the performance of the 28-gene panel that developed from the Asian breast cancer population with the 70-gene panel in Chinese women with EBC.
Methods
Pts with EBC, previously undergone 70-gene testing after primary surgery from Jan 2019 to Oct 2022 were enrolled. FFPE of primary breast tumors were collected for 28-gene testing. Clinicopathological risk factors such as diagnosed age ≤40y, ≥T2, N1, LVI positive, grade III, Ki-67≥ 20% were included in the final analyses. Pts with clinicopathological risk factors ≥2 were clinical high-risk (n=48); others were low-risk (n=51).
Results
A total of 99 Chinese pts with EBC (pT1-2N0-1 or pT3N0M0) were enrolled in this study, with a median diagnosed age of 52 years (29-74 years). The median follow-up period was 38 months, and the last follow-up date was June 20, 2023. Two pts were lost to follow-up, but none recurred or died. The 28-gene and 70-gene panels detected high-risk pts (26% vs. 34%) and low-risk (73% vs. 65%), respectively. The overall agreement of the two tests was 72% (71/99). In addition, the 28-gene panel showed higher consistency with clinical-risk prediction than the 70-gene panel (Kappa: 0.51 vs. 0.39). Among them, the consistency of the 28-gene panel and 70-gene panel with the low clinical-risk prediction was 98% (50/51) and 84% (43/51), respectively; the high-risk prediction was 47% (25/48) and 54% (26/48), respectively. Table: 10P
Risk prediction comparison of 28-gene and 70-gene panels
| Characteristic | 28-gene (%) | Kappa | 70-gene (%) | Kappa | |||
| High-risk | Low-risk | High-risk | Low-risk | ||||
| Clinical | High-risk | 25(25) | 23(23) | 0.51 | 26(26) | 22(22) | 0.39 |
| Low-risk | 1(1) | 50(51) | P<0.001 | 8(8) | 43(43) | P<0.001 | |
| Total | 26(26) | 73(74) | 99(100) | 34(34) | 65(66) | 99(100) |
Conclusions
The performance of the 28-gene panel in risk prediction of EBC was comparable with the 70-gene panel. The 28-gene panel could identify a more low-risk population in Chinese breast cancer pts. An enlarged sample size and longer follow-up for clinical outcomes will further confirm our conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key Research and Development Program of China (2019YFE0196500).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract